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Innovations
Corixa
Powering Immunotherapeutics
would focus on the development of velopment of immunotherapeutics.
Steve Gillis, now Corixa’s CEO, wasnew tools to fight infectious disease,
founder of Immunex and was a keysuch as therapeutic vaccines. Little
There is arguably no cellular system
in the human body more complex or
more diverse than the immune sys-
tem. The body’s ability to mount a player in Corixa’s genesis. Accord-attention was being paid in the early
successful attack upon a foreign ing to Grabstein, Gillis’ backing was90’s to the idea of therapeutic vac-
pathogen or wayward cancer cell re- instrumental. “Steve was well-cines—vaccines that could be used
quires the collaborative efforts of a known in the VC and industrial com-in individuals in whom infectious
myriad of different cell types, often munities, and his experience wasagents had already taken hold, such
with amusingly anthropomorphic ti- key to establishing and realizingas the growing legions of people liv-
tles such as “professional” antigen Corixa’s philosophy of partneringing with HIV. The vaccines of the day
presenting cells (APCs) and “helper” with big pharma.” Gillis elaborates,were primarily effective in generat-
or “killer” T cells. Our incomplete un- “Our philosophy has been to rely noting a humoral response, mediated
derstanding of the elegant complex- only on organic, internal discoveryby antibody-producing B cells, that
ity of the immune system has com- but also opportunistic product in-was only effective in preventing in-
plicated our efforts to exploit it in the licensing and company acquisition.fection by a microbe. However, once
battle against cancer and infectious This approach serves us well, partic-
and autoimmune disease. Until re- ularly in times when institutional
cently, our therapeutic weapons have investor interest is low.” The advan-
“We had learned that anbeen limited predominantly to pre- tages of this approach are compel-
ling, as Gillis explains, “Working withventative or prophylactic vaccines effective immune re-
and global immunomodulators like larger companies to develop certainsponse required activa-interferon or cyclosporin. The emer- products can provide valuable fi-
tion of the cellular arm ofgence of the human immunodefi- nancial resources as well as devel-
opment skills or marketing muscle.ciency virus (HIV) in the last quarter the immune system, but
of the last century added extra ur- Partnerships also diversify risk as-to accomplish this with agency to the need to decipher the sociated with biotechnology prod-
vaccine, we needed tocellular and molecular communica- uct development across the backs
of multiple stakeholders.”tions that lead to an effective im- develop technologies
mune response. An enthusiastic proponent ofthat could trigger andCorixa, a Seattle-based company Grabstein and Reed’s project from
boost the CTL response.”that develops immunotherapeutics, its inception, Gillis offered the duo
$3 million in funding from Immunex ifhopes to add significantly to our im- –Kenneth Grabstein, Cor-
munological armamentarium over they could find matching funds fromixa cofounderthe next few years. Corixa was cre- outside investors. 1993 was a tough
ated eight years ago this month, the year for biotech ventures looking for
result of a fittingly complex set of financing, however, and they came
microbes have invaded the cells ofcollaborations between both aca- back empty handed. As it turns out,
the body, a cellular response, medi-demic and industrial scientists, each Gillis was being courted around the
ated by T cells, is key, particularlybringing to the table his or her own same time by Joe Lacob of the influ-
for viruses or pathogens that live in-scientific or commercial expertise. ential venture capital firm Kleiner-
tracellularly, such as HIV or Leish-The company takes a collaborative Perkins, based in Menlo Park, Cali-
mania. Clearance of such agents re-approach to immunotherapeutics that fornia, to head up a company Lacob
quires cytotoxic T lymphocytes (CTLs)integrates a wide range of technol- was incubating to develop therapeu-
that actually seek out and destroyogy platforms, each of which alone tic vaccines—not against infectious
cells of the body that are infected.possesses significant partnering po- agents but against cancer, a poten-
“We had learned that an effectivetential with other developers of im- tially huge market. Lacob echoes
immune response required activa-munotherapeutics and vaccine tech- Grabstein’s views on Gillis’ star
tion of the cellular arm of the immunenology. power in the biotech arena. “Getting
system,” adds Grabstein, “but to ac-After twelve years at Seattle- a great CEO—one with vision and
complish this with a vaccine, webased Immunex, Corixa cofounder strong management experience—is
needed to develop technologies thatKenneth Grabstein was looking for a key to any successful venture, “ he
could trigger and boost the CTL re-new challenge. Together with Steve says, “and Steve (Gillis) was very at-
sponse.”Reed of the Seattle Biotechnology tractive to us for this reason.” Gillis
Immunex was one of the first bio-Research Institute (SBRI), he was in- realized that many of the challenges
the two groups were facing in devel-terested in founding a company that tech companies devoted to the de-
Chemistry & Biology
952
oping therapeutic vaccines were Their efforts have led to 800 “anti- boost antigen potency by effectively
flagging their presence to the im-similar, and he managed to get the gen” patent applications worldwide,
with about 120 already issued. Totwo groups working together. “At mune system. To date, most adju-
vants have worked by enhancing thefirst I thought the idea of merging be effective, these pathogen- or
cancer-associated antigens hadthe groups was unwise as it created antibody response. However, the
last decade has seen an explosiona broader focus for the company, also to be shown to induce an im-
mune response in the greatest frac-but the reality is that many of the of knowledge in the molecular and
cellular bases of T cell responses tonecessary technologies, from anti- tion of affected individuals. Ac-
cording to Reed, Corixa’s currentgen identification and delivery to ad- both viruses and cancer. Activation
of the cellular arm of the immunejuvants, were similar,” says Lacob, CSO, Corixa does this by focusing
on antigens that are recognized by“and when Gillis agreed to come on system is dependent upon a diverse
set of costimulatory signals that actboard to lead the new organization, the immune cells of those infected
individuals who show no signs ofI was convinced.” upon APCs. It is precisely these sig-
nals that adjuvants must trigger, andWhile Lacob’s venture had the disease, suggesting that the anti-
gens may offer protection. A tech-concept and the cash, he had yet to the family of Toll-like receptor (TLRs)
represents a particularly importantsecure the “scientific capital” in the nique known as “direct expression
cloning” can then be used to cloneform of people and technology. The nexus of such signals. Corixa scien-
tists have shown that TLR4 is a keytechnologies covered three impor- the genes that encode such an-
tigens.tant components of the antigenic re- target of MPL. MPL stands for mo-
nophosphoryl lipid A and is a deriva-sponse: antigens, adjuvants, and ef- These antigens can be exploited
for the development of other po-ficient ways of delivering the latter to tive of a bacterial endotoxin. The for-
mulation has either completed or isAPCs. Working together, the group tential therapeutics, such cancer-
fighting monoclonal antibodies ex-recruited top-notch scientific part- being tested in late-stage clinical
studies of vaccine formulations forners with the required expertise and emplified by Corixa’s BEXXAR, an
investigational radioimmunotherapylicensed their technology. These ac- both infectious diseases and can-
cer, and licenses have been grantedademic founders included Martin for non-Hodgkin’s lymphoma. BEX-
XAR incorporates a cytotoxic radio-“Mack” Cheever of the University of to both Glaxo-Smith-Kline and Wy-
eth-Lederle, two leading developersWashington and Olivera Finn from isotope into a monoclonal antibody
that targets a B-cell antigen on tu-the University of Pittsburgh, both en- of vaccines.
Knowledge that TLR4 is a targetgaged in the discovery of cancer an- mor cells. Acquired when the com-
pany took over Coulter Pharmaceu-tigens. They were joined by Kenneth for MPL has allowed Corixa to devel-
op small molecule agonists for theRock of Harvard University, an ex- ticals in December 2000, BEXXAR
has had a rough ride through thepert in the study of antigen presenta- receptor, such as their RC-529 com-
pound. This synthetic adjuvant hastion leading to a CTL response. FDA review process, however, and
additional studies have been re-Rock, too, had been thinking of set- shown good results in a phase III
clinical trial when used in conjunc-ting up a similar venture in the Bos- quested. Lacob freely admits that
the acquisition of Coulter and itston area, but was sufficiently im- tion with a yeast-based recombinant
hepatitis B antigen from Rhein-Bio-pressed with the Corixa blueprint to BEXXAR product was a costly one
for Corixa, and recent layoffs havethrow his hat in the ring. “I was im- tech, who inked a license and supply
agreement for RC-529 in April of thispressed by their integrated and been linked to its troubles. “We
knew we were taking a risk, but Icomprehensive approach,” he says, year. “Our partnership with Rhein-
Biotech affirms the potential value of“they saw the larger picture and un- remain very confident that the prod-
uct will be approved before not tooderstood that multiple components our proprietary adjuvant portfolio,”
says Gillis. The synthetic adjuvant ishad to be in place for an effective T long, “ says Lacob. The setback has
given a similar, competing productcell vaccine.” With a scientific team also in preclinical studies for use in
treating cancer and autoimmunein place, a venture capital round in from IDEC Pharmaceuticals (San
Diego) called Zevalin a head start in1994 raised $15 million based on the disease.
RC-529 is not the only productpremise that the company would fo- the market. According to Grabstein,
the eventual outcome of the BEX-cus on transactions and partner- Corixa is developing to fight autoim-
mune disease. Rheumatoid arthritisships with other biotech companies XAR review is key to Corixa’s future,
as it represents one of two productsand with big pharma. and multiple sclerosis are two condi-
tions in which the body erroneouslyAn early priority of the new com- on which the company is relying for
survival in the near term.pany was antigen discovery. The de- mounts a T cell response against a
self-antigen and attacks its ownvelopment of any vaccine, whether The other product is Corixa’s
powerful and popular MPL adjuvant,prophylactic or therapeutic, first re- cells. The better understanding we
now have of the T cell response isquires the identification of the anti- which came on board with another
of Corixa’s acquisitions, Ribi Immu-genic “Achilles’ heels” that trigger also providing strategies to fight
these diseases by manipulating thethe body to mount a response. noChem in 1999. Adjuvants repre-
sent a second important componentThese were the days of the so-called balance between antigen presenta-
tion and the costimulatory signals“genomic revolution,” as companies of successful vaccines. Most but not
all antigens are composed of shortraced to identify disease-related described earlier. Both inputs are
necessary, and if either is too greatgenes with the hopes of patenting polypeptides that are poorly immu-
nogenic on their own. Adjuvantsthem, and Corixa was no exception. or too small, the T cell response can
Innovations
953
be interrupted. In the case of RC- however, depends on a myriad of
factors in the world of biotech over529, the idea is to overload the co-
stimulatory response. In the case of which they have little control.
Corixa’s AnergiX treatments, the
Chemistry & Biology invites youridea is to overload the antigen-deliv-
comments on this topic. Pleaseery pathway. These products were
write to the editors at chembiol@once again the fruits of a strategic
cell.com.acquisition, that of Anergen. Once
APCs have taken up antigens, the Robert M. Frederickson is a freelance bio-
latter are bound to peptide binding tech writer based in Seattle (rfreder@
yahoo.com).receptors (major histocompatibility
complexes [MHC] class I or class II)
that sit on the outer membrane of
the cells. The MHC-antigen com-
plexes on APCs then bind and stim-
ulate CTLs and helper T cells. How-
ever, if the T cells do not receive
the costimulatory signals from the
APCs at the same time, they do not
respond. AnergiX products are solu-
ble MHC complexes previously
loaded with antigenic peptide that
bind the T cell receptors but bypass
the costimulatory signals, effectively
flooding out the APC cell-bound au-
toantigen and shutting down the au-
toimmune T cell reaction. Corixa has
partnered with Organon in the devel-
opment of such a formulation to
treat rheumatoid arthritis and with
Beaufour-Ipsen to treat myasthe-
nia gravis.
With the exceptions of the MELA-
CINE vaccine for melanoma (mar-
keted only in Canada at this point),
BEXXAR, and the MPL adjuvant
platform, the remainder of Corixa’s
vaccine products are either in early
clinical or preclinical stages of de-
velopment and are not predicted to
give rise to revenue for some time.
Indeed, Corixa continues to rely on
revenue from investors and partner-
ship deals, and they have their sights
set on technologies and patents held
by the vast number of small public
biotech companies, many of which
are left with less than a year of fund-
ing. Amazingly, given the current
market conditions in the biotech
community, the company did man-
age to pull off a private placement
in August 2002 worth about $45 mil-
lion—testimony to the influence of
Corixa’s management in the investor
community. This influence could be
key to Corixa’s survival and could
yet lead to profitability within the
next five years. Either way, what is
certain is that Corixa has put to-
gether the right components to suc-
ceed in the complex field of immu-
notherapeutics. Whether they do,
